the Company’s lead product
candidate remestemcel-L for the treatment of critically ill patients suffering with diseases caused by cytokine
release syndromes associated with high mortality, particularly COVID-19 acute respiratory distress syndrome
Ann: MSB Completes Financing For Covid-19 ARDS Manufacturing, page-33
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.025(2.45%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.04 | 99.5¢ | $4.379M | 4.328M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 163238 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 19700 | 2 |
View Market Depth
| Last trade - 16.10pm 01/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |